Almost every figure on the price boards is a cash price, and that is not a quirk of which companies get covered here. It follows from what is being sold. Understanding why makes the comparison between a covered prescription and a subscription purchase far less confusing than it first looks.
Why this market prices in cash
A pharmacy benefit pays claims against products listed on a formulary, and a formulary is assembled from products that went through approval. Compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.[1] A preparation that never entered that system has nothing for the claims machinery to match against.
So the cash model is structural rather than commercial. It also has consequences beyond the bill. In a nationwide primary-care records study, patients whose notes documented compounded formulations stayed on therapy longer on average than those on branded products — 10.0 months against 7.8 — and skewed toward people without diabetes living in less deprived areas.[2] A purchase made outside a benefit is a purchase made outside a lot of other machinery too.
One molecule, two coverage questions
Each of these molecules holds separate approvals under separate brand names, for separate indications, at different dose ceilings. That split is worked through in the article on the two approvals, and it matters here for a mundane reason: a benefit is written against a product and an indication, not against a molecule.
The practical consequence is that a plan can treat two chemically identical prescriptions differently depending on which brand is written and why. That is why checking coverage means checking a brand name and a diagnosis together, rather than asking whether the plan covers semaglutide.
The Medicare exclusion was written into the benefit
When the Medicare Part D benefit was constructed, drugs for weight loss were explicitly excluded from coverage. The reasoning at the time was about the medications then available: limited effectiveness, an unfavorable safety profile, and a perception that they were used cosmetically.[3]
That exclusion has been argued over ever since, and the argument is about money as much as medicine. One analysis estimated that covering anti-obesity medicines under Part D would raise annual costs by $3.1 billion or $6.1 billion, depending on whether 5% or 10% of newly eligible patients received one.[4] Policy in this area has moved repeatedly, so the durable advice is to read the current plan year rather than any general statement about Medicare.
Coverage that exists can be withdrawn
Commercial and employer coverage is not a fixed property of a plan. A study of one health system that discontinued GLP-1 coverage for obesity followed 247 adults who lost it. Afterward, 80.57% reported worsened perceptions of their employer and 17.81% said they had considered changing jobs.[5]
The finding worth carrying into a purchasing decision is the simple half: a benefit that pays this year may not pay next year. That matters more for this drug class than for most, because stopping has been measured directly and the result is documented in the withdrawal trials. A plan that depends on coverage continuing is worth stress-testing before it starts.
How to check, rather than guess
Four questions do most of the work, and all four are answered by the plan rather than by any website. Is weight management a covered benefit category under this plan at all? Is the specific brand name on the formulary, and at which tier? What does prior authorization require, and does step therapy apply first?
The fourth is the one that produces a comparable figure: what is the monthly cost-sharing once the deductible phase is accounted for? That number, not the list price and not the copay quoted in an advertisement, is what sits beside a cash price on equal terms.
Manufacturer savings programs sit alongside all of this and follow their own rules. They attach to branded products, typically set eligibility conditions such as holding commercial coverage, commonly exclude people with federal benefits, and often cap the monthly saving. Those terms are published by each program and revised periodically, so they are worth reading at the source rather than from a seller’s summary.
Comparing the two routes without fooling yourself
A covered branded prescription and a cash compounded subscription are not two prices for one product, for reasons set out in the article on that gap. Treating them as interchangeable line items is the commonest error in this whole comparison.
Where they can be compared is on total outlay across the horizon you expect. A cash price is knowable in advance and stays knowable, unless it moves with the dose; sellers that hold one price across every dose make that arithmetic simple. A covered price is often lower and less predictable, because it shifts with deductible phase, formulary tier and plan year.
Neither route is the right answer in general. A reader with a benefit that covers an approved product at a modest copay is usually looking at a different and better proposition than the cash market offers. A reader with no such benefit is looking at what the seller write-ups record, and at a purchase that has to be judged on its own terms.
What this page cannot tell you
Nothing here describes anyone’s coverage. Two people working for the same employer, on different plans, in different states, can get different answers about the same prescription in the same week. Plan design is that variable, and no general page can shortcut it.
The documents that govern are the plan’s own: the formulary for the current year, the medical policy for weight management, and the prior-authorization criteria. What is published on this site is the cash side of the market and how those figures are produced, which is set out in the methodology.